GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » Price-to-Owner-Earnings

Orchestra BioMed Holdings (Orchestra BioMed Holdings) Price-to-Owner-Earnings : (As of Jun. 04, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings Price-to-Owner-Earnings?

As of today (2024-06-04), Orchestra BioMed Holdings's share price is $7.69. Orchestra BioMed Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Orchestra BioMed Holdings's Price-to-Owner-Earnings or its related term are showing as below:


OBIO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.035
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-04), Orchestra BioMed Holdings's share price is $7.69. Orchestra BioMed Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.48. Therefore, Orchestra BioMed Holdings's PE Ratio for today is At Loss.

As of today (2024-06-04), Orchestra BioMed Holdings's share price is $7.69. Orchestra BioMed Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.45. Therefore, Orchestra BioMed Holdings's PE Ratio without NRI for today is At Loss.


Orchestra BioMed Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Orchestra BioMed Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchestra BioMed Holdings Price-to-Owner-Earnings Chart

Orchestra BioMed Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - -

Orchestra BioMed Holdings Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orchestra BioMed Holdings's Price-to-Owner-Earnings

For the Biotechnology subindustry, Orchestra BioMed Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orchestra BioMed Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Orchestra BioMed Holdings's Price-to-Owner-Earnings falls into.



Orchestra BioMed Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Orchestra BioMed Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=7.69/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orchestra BioMed Holdings  (NAS:OBIO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Orchestra BioMed Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description

Traded in Other Exchanges
N/A
Address
150 Union Square Drive,, New Hope, PA, USA, 18938
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Executives
George Papandreou officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Eric S Fain director ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
David P Hochman director, officer: See Remarks 15 WESTON HILL RD., RIVERSIDE CT 06878
Joshua Aiello officer: Principal Accounting Officer 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika officer: See Remarks 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Darren Sherman director, officer: See Remarks C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Plc Medtronic 10 percent owner 20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan officer: Chief Financial Officer KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith director 6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014